OncoCyte Corp Insiders
| OCXDelisted Stock | USD 3.20 0.43 15.52% |
OncoCyte Corp employs about 46 people. The company is managed by 26 executives with a total tenure of roughly 88 years, averaging almost 3.0 years of service per executive, having 1.77 employees per reported executive. Break down of OncoCyte Corp's management performance can provide insight into the company performance.
OncoCyte |
OncoCyte Corp Management Team Effectiveness
The company has Return on Asset of (0.2217) % which means that on every $100 spent on assets, it lost $0.2217. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (4.2896) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities.OncoCyte Corp owns a total of 28.6 Million outstanding shares. Over half of OncoCyte Corp's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as OncoCyte Corp in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of OncoCyte Corp, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
OncoCyte Corp Workforce Comparison
OncoCyte Corp is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,029. OncoCyte Corp holds roughly 46.0 in number of employees claiming about 4% of equities under Health Care industry.
OncoCyte Corp Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OncoCyte Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on OncoCyte Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, OncoCyte Corp insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
OncoCyte Corp Notable Stakeholders
An OncoCyte Corp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as OncoCyte Corp often face trade-offs trying to please all of them. OncoCyte Corp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting OncoCyte Corp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael West | Director, CEO of Biotime Inc and President of Biotime Inc | Profile | |
| Ronald Andrews | President, Chief Executive Officer, Director | Profile | |
| Mitchell Levine | Chief Financial Officer | Profile | |
| Albert Parker | Chief Operating Officer | Profile | |
| Peter Hong | General VP | Profile | |
| Andrea James | Chief Officer | Profile | |
| Ekkehard MD | Chief Officer | Profile | |
| Joshua Riggs | Interim Officer | Profile | |
| Tony Kalajian | Senior Vice President Chief Accounting Officer | Profile | |
| Andrew Last | Independent Director | Profile | |
| William Annett | Advisor | Profile | |
| Gabrielle Woody | Executive Assistant | Profile | |
| Sara Riordan | Director Education | Profile | |
| Lyndal Hesterberg | Chief Scientific Officer | Profile | |
| Robert Seitz | Head Oncology | Profile | |
| James Liu | Treasurer, Accounting | Profile | |
| YuhMin Chiang | Senior Development | Profile | |
| Douglas Ross | Chief Medical Officer | Profile | |
| Melinda Griffith | Independent Director | Profile | |
| Anish John | Chief Officer | Profile | |
| Andrew Arno | Independent Director | Profile | |
| Gisela Paulsen | COO Pres | Profile | |
| Cavan Redmond | Independent Chairman of the Board | Profile | |
| Padma Sundar | Senior Vice President - Marketing and Market Access | Profile | |
| MD FACP | Consulting Officer | Profile | |
| Sandra ODonald | Senior Operations | Profile |
About OncoCyte Corp Management Performance
The success or failure of an entity such as OncoCyte Corp often depends on how effective the management is. OncoCyte Corp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of OncoCyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the OncoCyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Oncocyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.
Please note, the imprecision that can be found in OncoCyte Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of OncoCyte Corp. Check OncoCyte Corp's Beneish M Score to see the likelihood of OncoCyte Corp's management manipulating its earnings.
OncoCyte Corp Workforce Analysis
Traditionally, organizations such as OncoCyte Corp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare OncoCyte Corp within its industry.OncoCyte Corp Manpower Efficiency
Return on OncoCyte Corp Manpower
| Revenue Per Employee | 40.9K | |
| Revenue Per Executive | 72.3K | |
| Net Loss Per Employee | 1.3M | |
| Net Loss Per Executive | 2.3M | |
| Working Capital Per Employee | 97.5K | |
| Working Capital Per Executive | 172.5K |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in OncoCyte Stock
If you are still planning to invest in OncoCyte Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoCyte Corp's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |